GlassScriptPhysician profile
Luis J Batlle
NPI 1518192343
$14,070.17
in general payments reported to CMS, 2019-2025
37 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $467 · 2021: $1,384 · 2022: $1,214 · 2023: $1,511 · 2024: $6,367 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,536 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,114 · Honoraria: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,113.50 |
| Honoraria | $1,916.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $5,437.95 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $1,466.25 | 2019-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $1,167.28 | 2019-2025 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $975.58 | 2019-2025 | Relistor |
| Abbvie INC. | $885.08 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Boston Scientific Corporation | $853.96 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Ibsa Pharma INC. | $488.87 | 2021-2025 | Tirosint, Licart, Tirosint |
| Pfizer INC. | $450.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $356.28 | 2019-2022 | |
| Nevro Corp. | $348.04 | 2019-2024 | Senza |
| Lilly USA, LLC | $176.07 | 2020-2023 | Reyvow, Emgality |
| Bausch Health US, LLC | $160.67 | 2019-2020 | |
| Allergan, INC. | $132.46 | 2020-2022 | |
| Redhill Biopharma INC. | $118.10 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $111.23 | 2023-2024 | Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.88 | 2019-2022 | |
| Medtronic, INC. | $103.85 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $100.13 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $70.07 | 2019-2021 | |
| Globus Medical, INC. | $69.00 | 2025 | Senza |
| Upsher-Smith Laboratories LLC | $65.69 | 2022 | |
| Protega Pharmaceutials INC | $61.49 | 2022-2024 | Roxybond |
| Eisai INC. | $59.00 | 2021-2022 | |
| Saluda Medical Americas, INC. | $50.82 | 2024-2025 | Evoke |
| Arbor Pharmaceuticals, INC. | $47.01 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $37.19 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.94 | 2021 | |
| Electronic Waveform Lab, INC. | $20.28 | 2021 | |
| Daiichi Sankyo INC. | $19.30 | 2019 | |
| Lundbeck LLC | $18.07 | 2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $16.09 | 2019 | |
| Breg, INC | $15.63 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.48 | 2022 | |
| Forte Bio-Pharma LLC | $14.08 | 2024 | Prolate, Nalocet |
| Valinor Pharma, LLC | $13.83 | 2025 | Movantik |
| Uswm, LLC | $11.64 | 2021 | |
| Relievant Medsystems, INC. | $8.75 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Batlle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.